Mirum Pharmaceuticals Inc reported that its experimental hepatitis delta treatment, brelovitug, lowered virus levels and normalized liver enzymes in a second late-stage study. The trial enrolled 113 previously untreated patients with advanced liver scarring. The data supports a planned United States approval application slated for early 2027.
Mirum drug meets goals in late-stage study
Mirum Pharmaceuticals announced its hepatitis delta treatment successfully reduced virus and liver enzyme levels in a second late-stage study. The company plans to seek US approval in the first half of 2027 following positive trial data.
Xurve View
Insights:
Xurve View
